ASCO Annual Meeting

Vepdegestrant significantly improved progression-free survival vs fulvestrant in pretreated ESR1-mutant, ER-positiver, HER2-negative advanced breast cancer.

Sacituzumab govitecan & pembrolizumab significantly improved PFS in PD-L1+ advanced TNBC vs. chemo/pembrolizumab in the ASCENT-04 study.

Ibrahim Aldoss, MD, discusses a post hoc analysis of ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who did not achieve early MRD negativity.

Christopher Danes, PhD, discusses how patient and caregiver priorities and concerns vary during the course of treatment for non–small cell lung cancer.

Sara M. Tolaney, MD, MPH, highlights a transformative year for breast cancer research at this year’s ASCO Annual Meeting.

Christopher Danes, PhD, discusses a study exploring the differences in priorities for patients and their caregivers when undergoing treatment for non–small cell lung cancer.

Ayal Aizer, MD, MHS, discusses the unmet needs in treating patients with brain metastases.

Neel Shah, MD, and Manmeet Ahluwalia, MD, MBA, FASCO, discuss what they look most forward to hearing about and learning at the 2025 ASCO Annual Meeting.

As the oncology community prepares for the 2025 American Society of Clinical Oncology Annual Meeting, anticipation is running high over a wave of potential practice-changing data sets to be unveiled.

The ASCO 2025 press briefing showcased early highlights in cancer therapy. Here’s what you need to know.

A large study found GLP-1 drugs don't raise cancer risk; instead, they cut obesity-related cancers by 7% and overall mortality by 8%.

INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant advanced breast cancer.

AI-assisted training notably improved pathologist accuracy in HER2-low breast cancer, reducing misclassification and potentially enabling more patients to access vital therapies.

Lurbinectedin plus atezolizumab maintenance significantly improved PFS & OS in extensive-stage SCLC, offering a potential new standard of care.

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.

Juneko Grilley-Olson, MD, discussed findings from a phase 2 study investigating the addition of immunotherapy to chemotherapy for the treatment of advanced angiosarcoma.

Barbara O'Brien, MD, discusses the goals and results of a study investigating tucatinib, trastuzumab, and capecitabine for the treatment of leptomeningeal metastases in patients with HER2-positive breast cancer.

Denise Yardley, MD, discusses the takeaways and next steps of an analysis of the NATALEE trial investigating ribociclib in node-negative breast cancer.

Maya Dimitrova, MD, discusses areas of further research and unmet needs for patients with melanoma.

Elizabeth Loggers, MD, PhD, discussed the phase 3 DeFi study exploring ovarian toxicity in female patients receiving nirogacestat for the treatment of desmoid tumors.

Xiaolin Zhang, PhD, discusses findings from the phase 2 study exploring a novel oral agent for the treatment of EGFR-mutated non–small cell lung cancer.

Mariam Eskander, MD, MPH, discussed a study exploring how inequity and social vulnerability factor into clinical trial enrollment.

Mina Lobbous, MD, MPH, discusses findings and implications fro a study investigating a new regimen for the treatment of brain metastases in patients with HER2-positive breast cancer.

Neil Segal, MD, discussed findings from a phase 1/2 trial investigating REGN7075 in patients with solid tumors refractory to immunotherapy.

Ravi Parikh, MD, MPP, discusses findings and implications of a study exploring algorithm-based palliative care recommendations.

Nikhil Khushalani, MD, discussed a phase 3 study investigating fianlimab plus cemiplimab vs nivolumab and relatlimab for the treatment of patients with advanced melanoma.

Elizabeth Logers, MD, PhD, discusses the implications of ovarian toxicity on female patients of reproductive age being treated with nirogacestat for desmoid tumors.

David Spigel, MD, discussed the findings and implications from the phase 3 ADRIATIC study of durvalumab in small cell lung cancer presented at the 2024 ASCO Annual Meeting.

Andrea Roman, PharmD, BCOP, discusses findings from a study investigating the benefits of remote oncology pharmacists.

Christopher Moertel, MD, discusses mirdametinib's mechanism of action and the implications of the phase 2b ReNeu trial of the agent in NF1-associated plexiform neurofibroma.